Results of the validation study
For the validation study, an additional 100 patients (54 men, mean age
57.63 ±11.44 years, and 46 women, mean age 63.54 ±9.55 years) who
underwent successful ablation in either the RVOT or the LVOT were
enrolled. According to the successful ablation site, in 66 (66.00%)
patients, the VAs had originated in the RVOT, and in 34 (34.00%)
patients, the VAs had originated in the LVOT. The LVOT group comprised
18 (52.94%) patients with LCC, 5 (14.71%) with RCC, 10 (29.41%) with
left ventricular endocardium below the ASC, and 1 (2.94%) with GCV-AIV.
In the validation study,
our
ECG
algorithm
exhibited excellent accuracy (95.00%) and AUC (0.95), with a
sensitivity of 94.12%, a specificity of 95.45%, a PPV of 91.43%, and
an NPV of 96.92%.